top of page


OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion
OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.

nuaxia
1 day ago2 min read


argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery
argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics.

nuaxia
Nov 102 min read


Zealand Pharma signs AI protein therapeutics collaboration with Generate Biomedicines worth over $1 billion
Zealand Pharma and Generate Biomedicines have signed an AI-enabled protein therapeutics collaboration for obesity and metabolic diseases with potential milestone payments approaching $1.2 billion.

nuaxia
Oct 152 min read


GSK expands AI drug discovery collaboration with Chai Discovery following successful laboratory evaluation
GSK has expanded its collaboration with Chai Discovery to apply AI-powered protein modelling and molecular design tools across pharmaceutical drug discovery following successful laboratory validation.

nuaxia
Oct 142 min read


Pfizer signs Enodia Therapeutics research and licensing agreement worth more than $500 million for Sec61 protein degradation
Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition.

nuaxia
Oct 142 min read


Roche partners with Defand Therapeutics to discover molecular glue drugs for cancer and immune diseases
Roche and Defand enter molecular glue discovery collaboration targeting cancer and immune-mediated diseases

nuaxia
Oct 92 min read


Lilly expands Gate Bioscience collaboration for molecular-gate protein degraders
Eli Lilly and Gate Bioscience have expanded their drug-discovery collaboration by adding a new target and an option for a second under Gate's Molecular Gate platform.

nuaxia
Oct 72 min read


Lilly and InnoCare sign drug-discovery collaboration worth up to $3.35bn
Lilly and InnoCare have entered a multi-target research and licensing collaboration potentially worth $3.35 billion to discover and develop new medicines.

nuaxia
Sep 252 min read


Arcturus Therapeutics agrees acquisition of AI drug-discovery company myNEO
Arcturus Therapeutics has agreed to acquire Belgian AI drug-discovery company myNEO, expanding its computational capabilities for mRNA medicine design and target identification.

nuaxia
Sep 252 min read


AbbVie and Iambic enter AI-driven drug discovery collaboration across immunology, neuroscience and oncology
AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

nuaxia
Sep 222 min read


Novo Nordisk and Orbis Medicines sign macrocycle discovery deal worth up to $1.4bn
Novo Nordisk and Orbis Medicines have entered a multi-target drug-discovery partnership worth up to $1.4 billion to develop orally bioavailable macrocycle medicines for cardiometabolic disease.

nuaxia
Sep 182 min read


Roche and Dualitas enter bispecific discovery collaboration worth more than $1bn
Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.

nuaxia
Sep 182 min read


Monod Bio licenses AI-designed protein technologies to SignalChem for drug discovery assays
The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

nuaxia
Aug 273 min read


Lilly signs OmniAb ion channel discovery deal with up to $370 million in milestones
The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.

nuaxia
Aug 192 min read


Aizen Therapeutics signs AI peptide collaboration worth up to $100 million per target
The multi-program deal pairs Aizen’s DaX AI platform with an undisclosed San Diego biotechnology company to design oral peptide therapeutics against nominated immunology and neurology targets.

nuaxia
Aug 173 min read


Ono Pharma partners with Mediar Therapeutics to discover antibody therapies for fibro-inflammatory diseases
The research collaboration combines Mediar’s fibrosis biology and antibody discovery capabilities with Ono’s drug development expertise to identify new treatments targeting fibro-inflammatory disease mechanisms.

nuaxia
Aug 72 min read
bottom of page